Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.…
Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease
Nexalin Technology (NASDAQ: NXL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 8 employees.
The shares were at 1.380 USD on 20 November 2026, down 96.3% over 52 weeks. Its 52-week range is 1.310 USD to 40.80 USD: the price is 96.6% below the high and 5.3% above the low.
Its market capitalisation is 1.71M USD.
Nexalin Technology reports return on equity of -219.4% and revenue down 82.8% year over year.
It holds more cash than debt, a net cash position of 1.00M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.